Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Hemophilia B Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Hemophilia B Pipeline Insight 2024' report details 20+ pipeline drugs from 15+ companies, focusing on mechanism of action, route of administration, and molecule types. Key companies include Belief Biomed, TiumBio, and Pfizer, with therapies in various clinical stages. Notable recent developments include Novo Nordisk and ApcinteX trials in May 2024.
Why clinical trials are rarely conducted in Sub-saharan Africa
Pharmaceutical companies conduct most clinical trials in countries where they plan to market products, often neglecting low and middle-income countries (LMICs), particularly in sub-Saharan Africa. This exclusion limits access to life-saving treatments and therapies for patients in these regions. The Access to Medicine Foundation report highlights a gap in product registration in Africa, with 43% of innovative products approved in the past five years not registered in any African countries. The report calls for pharmaceutical companies to prioritize equitable access and work with local partners to build research capabilities in LMICs.
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for ...
Innovent Biologics announces the inclusion of SINTBILO® (tafolecimab injection) in the 2024 National Reimbursement Drug List (NRDL) for treating primary hypercholesterolemia and mixed dyslipidemia, and the addition of a new indication for olverembatinib, a BCR-ABL inhibitor, effective from January 1, 2025.
IgG4-Related Disease Clinical Trials 2024: EMA, PDMA, FDA
The article highlights the ongoing clinical trials and developments in the treatment of IgG4-Related Disease (IgG4-RD), a chronic immune-mediated condition affecting multiple organs. Key companies like Amgen, Sanofi, and Zenas Biopharma are advancing therapies such as UPLIZNA and obexelimab, with significant progress reported in Phase III trials. The disease's complexity, involving fibrosis and inflammation, underscores the importance of early diagnosis and treatment, primarily with corticosteroids or immunosuppressive agents for refractory cases.
Rilzabrutinib & First Biosimilar Golimumab Among New EU Filings
Sanofi’s rilzabrutinib and Alvotech/Advanz Pharma’s golimumab (AVT05) are among five new entries on the European Medicines Agency’s latest monthly list of products under review. Both drugs are investigational and unapproved globally.
Sanofi launches world's first modular concept manufacturing facility to Singapore
Sanofi inaugurated Modulus, a state-of-the-art, sustainable biopharmaceutical manufacturing facility in Singapore, leveraging a modular concept for flexible production of next-generation vaccines and biological medicines, aiming to be fully operational by mid-2026.
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Vir Biotechnology to host virtual investor event on Jan 8, 2025, discussing initial data from Phase 1 T-cell engagers VIR-5818 and VIR-5500, and updates on the PRO-XTEN™ platform.
© Copyright 2025. All Rights Reserved by MedPath